Phio Pharmaの空売り状況は、投資家がPhio Pharmaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Phio Pharma (NASDAQ:PHIO) 株価情報, 空売り情報

Phio Pharma

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharmaceuticals Corp

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares settled slightly higher during <a href="https://www.benzinga.com/markets/equities/24/12/42664887/apples-near-term-success-will-be-driven-by-strong-holiday-season-iphone-16-says-dan-ives-analyst-sees-stock-hitting-300-cupertino-hitting-4-trillion-marketcap">Monday's session</a>.
Apple is on track to become the first company to reach a $4 trillion market capitalization by "early 2025," driven by strong iPhone sales and artificial intelligence innovations, according to Wedbush Securities analyst Dan Ives.
The tech giant's shares have surged nearly 40% since January, closing at $255 per share on Monday with a market cap of $3.86 trillion. This performance puts Apple ahead of rivals NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) at $3.35 trillion and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) at $3.22 trillion.
With the recent buzz around Apple, some investors may be eyeing potential gains from the company's dividends too. Currently, Apple offers an annual dividend yield of 0.39%, a quarterly dividend amount of 25 cents per share ($1.00 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $1,531,620 or around 6,000 shares. For a more modest $100 per month or $1,200 per year, you would need $306,324 or around 1,200 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.00 in this case). So, $6,000 / $1.00 = 6,000 ($500 per month), and $1,200 / $1.00 = 1,200 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
AAPL Price Action: Shares of Apple gained 0.3% to close at $255.27 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>
Photo: Shutterstock

Long Ideas

News

Markets

Trading Ideas

AAPL

MSFT

NVDA

How To Earn $500 A Month From Apple Stock

Macro Economic Events

Econ #s

Economics

USA Redbook (YoY) 5.9% Vs 4.8% Prior

NEUP

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Evercore ISI Group analyst Steve Sakwa maintains Urban Edge Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UE#NYSE">UE</a>) with a In-Line and lowers the price target from $23 to $22.

Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on Urban Edge Props, Lowers Price Target to $22

Evercore ISI Group analyst Steve Sakwa maintains Regency Centers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>) with a In-Line and lowers the price target from $78 to $77.

Evercore ISI Group Maintains In-Line on Regency Centers, Lowers Price Target to $77

WIIM

NEUE

NeueHealth shares are trading higher after the company announced it has entered into an definitive merger to be acquired for $7.33 per share.

INSW

International Seaways shares are trading higher after it was announced that the company will join the S&P SmallCap 600 on December 30, 2024.

Evercore ISI Group analyst Steve Sakwa maintains Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) with a In-Line and lowers the price target from $24 to $23.

Evercore ISI Group Maintains In-Line on Kimco Realty, Lowers Price Target to $23

CREV

Carbon Revolution shares are trading higher after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.

Evercore ISI Group analyst Samir Khanal maintains Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) with a In-Line and lowers the price target from $32 to $31.

Evercore ISI Group Maintains In-Line on Brixmor Property Group, Lowers Price Target to $31

Dollar Gen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) short percent of float has risen 14.56% since its last report. The company recently reported that it has 8.27 million shares sold short, which is 4.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dollar Gen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735047921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dollar Gen has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Dollar Gen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dollar Gen's peer group average for short interest as a percentage of float is 3.44%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Dollar Gen?

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has fallen 9.01% since its last report. The company recently reported that it has 3.39 million shares sold short, which is 3.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735047916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 4.97%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ALNY

How Is The Market Feeling About Alnylam Pharmaceuticals?

Dollar Tree's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NYSE">DLTR</a>) short percent of float has fallen 22.06% since its last report. The company recently reported that it has 9.53 million shares sold short, which is 5.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dollar Tree Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735047911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dollar Tree has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dollar Tree's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dollar Tree's peer group average for short interest as a percentage of float is 3.30%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

DLTR

Looking Into Dollar Tree's Recent Short Interest

As of Dec. 24, 2024, two stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 7</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">LexinFintech Holdings Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>)</h3>
<ul>
<li>On Nov. 25, LexinFintech announced its board approved an amendment for a dividend policy to increase the payout ratio. Also, the company reported third-quarter financial results. The company's stock surged around 76% over the past month and has a <a href="https://www.benzinga.com/quote/LX">52-week high of $6.28</a>.</li>
<li>RSI Value: 70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LX Price Action: Shares of LexinFintech closed at $5.99 on Monday.</li>
</ul>
<h3 class="wp-block-heading">AppTech Payments Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>)</h3>
<ul>
<li>On Dec. 17, AppTech Payments announced it received a $5 million investment from AFIOS Partners and is restructuring its board by appointing three new directors. AppTech&#8217;s Chairman, Luke D&#8217;Angelo stated, &#8220;We genuinely appreciate our outgoing board members&#8217; unwavering dedication to AppTech. We are excited to work with our new AFIOS partners, who are clearly focused on near- and long-term value creation. &#8221; The company's stock gained around 86% over the past five days and <a href="https://www.benzinga.com/quote/APCX">has a 52-week high</a> of $2.30.</li>
<li>RSI Value: 73</li>
<li>APCX Price Action: Shares of AppTech Payments closed at $0.84 on Monday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

Pre-Market Outlook

APCX

Top 2 Financial Stocks That May Keep You Up At Night This Month

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/12/23/final-trades-zoom-video-lockheed-martin-and-the-iwd.html">Halftime Report Final Trades</a>,&#8221; Joseph M. Terranova of Virtus Investment Partners said Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is one of his favorite <a href="https://www.benzinga.com/news/management/24/11/42176089/zoom-communications-q3-earnings-revenue-beat-eps-beat-online-churn-hits-all-time-low-company-name-change-and-more">stocks to own in 2025</a>.
On Nov. 25, Zoom reported third-quarter revenue of $1.18 billion, beating the consensus estimate of $1.16 billion. The communications company reported third-quarter adjusted earnings of $1.38 per share, beating analyst estimates of $1.31 per share.
On Dec. 19, Jefferies analyst Samad Samana upgraded Zoom Communications from Hold to Buy and raised the price target from $85 to $100.
Jim Lebenthal of Cerity Partners named Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) as his final trade.
On Dec. 16, Lockheed Martin revealed the launch of the seventh Lockheed Martin-designed and built Global Positioning System (GPS) III satellite, GPS III SV07, at 7:52 p.m. ET. The GPS III SV07 spacecraft, built at Lockheed Martin's Littleton, Colorado, facility, was transported by ground to its Florida launch site after its usual military aircraft was reassigned <a href="https://www.benzinga.com/24/12/42527692/mission-accomplished-lockheed-martins-gps-iii-sv07-successfully-deployed">for hurricane relief efforts.</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Rob Sechan of NewEdge Wealth picked iShares Russell 1000 Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWD#NYSE">IWD</a>).
Price Action:
<ul>
<li>Zoom shares fell by 0.4% to close at $85.27 on Monday.</li>
<li>Lockheed Martin shares fell 0.5% to close at $486.49 during Monday's session.</li>
<li>iShares Russell 1000 Value ETF rose 0.2% on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Media

Zoom Communications, Lockheed Martin And More: CNBC's 'Final Trades'

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology.
Under the terms of the agreements, a deferred consideration payment of $5 million related to the acquisition of the biosensor assets of Waveform Technologies has been extended to November 2025, offering the Company greater financial flexibility. In addition, further additional liquidity in the amount of approximately $5.5 million has been provided to Trinity Biotech through a combination of cash and payment-in-kind interest, strengthening liquidity during this pivotal period of transformation. As part of the agreement, Trinity Biotech has granted Perceptive Advisors 1.5 million additional warrants to purchase the Company's ADS, and repriced its existing ADS warrants at an exercise price of $0.80 per ADS, reinforcing the ongoing partnership between the two entities.

Offerings

Management

TRIB

Trinity Biotech Amends Credit Agreement With Perceptive Advisors To Boost Liquidity And Support Transformation Plan; Secures $5.5M In Additional Funding, Extends $5M Payment To 2025, And Issues 1.5M New Warrants At $0.80 Exercise Price

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Equity Commonwealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQC#NYSE">EQC</a>)</h3>
<ul>
<li>On Nov. 26, Equity Commonwealth completed the sale of 1250 H Street. The company's stock fell around 91% over the past month and has a <a href="https://www.benzinga.com/quote/EQC">52-week low of $1.40</a>.</li>
<li>RSI Value: 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>EQC Price Action: Shares of Equity Commonwealth fell 1.7% to close at $1.74 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1">latest EQC news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="878" height="782" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083110/image-196.png" alt="" class="wp-image-705981" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083110/image-196.png 878w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083110/image-196-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083110/image-196-768x684.png 768w" sizes="(max-width: 878px) 100vw, 878px" /></a></figure>
<h3 class="wp-block-heading">Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</h3>
<ul>
<li>On Nov. 15, Wheeler Real Estate Investment Trust announced a 1-for-2 reverse stock split. The company's stock fell around 52% over the past month and &lt;a href=&#8221;https://www.benzinga.com/quote/WHLR&#8221;&gt;&lt;em&gt; has a 52-week low &lt;/em&gt;&lt;/a&gt; of $3.75.</li>
<li>RSI Value: 24</li>
<li>WHLR Price Action: Shares of Wheeler Real Estate Investment Trust closed at $4.05 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1">trend in WHLR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="921" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083138/image-197.png" alt="" class="wp-image-705982" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083138/image-197.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083138/image-197-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083138/image-197-768x685.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>)</h3>
<ul>
<li>On Nov. 6, LXP Industrial Trust reported better-than-expected third-quarter financial results. T. Wilson Eglin, Chairman and Chief Executive Officer of LXP, commented &#8220;We posted strong third-quarter results with same-store NOI growth of 5.4% driven by 39.1% cash rental increases on second generation leases completed through September 30, 2024. We made progress on development leasing, executing a five-year lease at our 250,000 square foot development project in Columbus with a development yield of 8.5% and 3.5% annual rental increases." The company's stock fell around 12% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/LXP">low of $8.08</a>.</li>
<li>RSI Value: 29</li>
<li>LXP Price Action: Shares of LXP Industrial Trust fell 0.5% to close at $8.28 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1">breakout in LXP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="877" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083244/image-198.png" alt="" class="wp-image-705983" style="width:697px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083244/image-198.png 877w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083244/image-198-300x289.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083244/image-198-768x740.png 768w" sizes="(max-width: 877px) 100vw, 877px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

WHLR

Top 3 Real Estate Stocks Which Could Rescue Your Portfolio For Q4

Offering Real-Time Availability, Transparent Pricing, And Seamless Trip Management; Updates CharterGPT App With Carbon Tracking, Push Notifications, And Deep Linking.

JTAI

Jet.AI Launches "Ava," An Agentic AI Model For Private Jet Booking

Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year warrants, both priced at $0.23 per share, in a private placement for aggregate gross proceeds of $1.85 million before deducting offering expenses and fees (the "Private Placement"). The warrants, if exercised, will result in an additional $1.85 million in proceeds to Carmell. The Private Placement was priced at a slight premium to the CTCX closing price on December 23, 2024.
Said Mr. Rajiv Shukla, Chairman of Carmell, "We are happy to announce an additional round of investment from existing and new investors to support the continued commercial build out of our revolutionary bio-aesthetics product pipeline."

CTCX

Carmell Enters Securities Purchase Agreement With New And Existing Investors For The Issuance And Sale Of 8,065,210 Shares Of Its Common Stock And An Equal Number Of 5-Year Warrants, Both Priced At $0.23 Per Share, In A Private Placement For Aggregate Gross Proceeds Of $1.85M

NANO Nuclear acquires Micro Modular Reactor (MMR&#xAE;) and Pylon technologies, including all associated patents, through a Chapter 11 bankruptcy auction
New York, N.Y., Dec. 24, 2024 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing portable, clean energy solutions, today announced that it has executed a definitive agreement to acquire select nuclear energy technology assets from Ultra Safe Nuclear Corporation and certain of its subsidiaries (collectively, "USNC").
The acquired assets include USNC's patented Micro Modular Reactor (MMR&#xAE;) system, along with all associated patents and other intellectual property rights, as well as its Pylon reactor technology and related intellectual property, and certain demonstration project partnerships related to the MMR system. The assets are being acquired for $8.5 million in cash through an auction process conducted pursuant to Section 363 of the U.S. Bankruptcy Code in connection with USNC's pending Chapter 11 bankruptcy proceedings. On December 18, 2024, the United States Bankruptcy Court for the District of Delaware, the Bankruptcy Court overseeing USNC's chapter 11 case, conducted a hearing and approved the transaction. The closing of the acquisition is expected to occur in the near future subject to satisfaction of customary closing conditions in a bankruptcy proceeding.

NANO Nuclear Energy Enters Into Agreement To Acquire Ultra Safe Nuclear Corp.'s Patented Micro Modular Reactor MMR And Pylon Space Reactors For $8.5M Along With Worldwide Demonstration Partnerships

Warning: PHIO is at high risk of performing badly

Phio Pharmaceuticals GAAP EPS of -$1.54 beats by $2.60

PHIO

Press Releases

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Comments

Phio Pharma

空売り

Phio Pharma (NASDAQ:PHIO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル